Once-Daily, Dual Mechanism Antibiotic Possesses Profile to Play Key Role in Global Fight Against Antimicrobial Resistance FOSTER CITY, CA and GEORGE TOWN, GRAND CAYMAN–(Marketwired – May 27, 2015) – SciClone Pharmaceuticals (NASDAQ: SCLN), (“SciClone”), a U.S.-based, China-focused specialty pharmaceutical company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”), through an affiliate, today announced they have entered […]

ELSTREE, U.K. & DURHAM, N.C.–(BUSINESS WIRE)–Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s amended Biologics License Application for Coagadex® for hereditary factor X deficiency. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal […]

Freshly IPO’d bluebird bio (BLUE) will pay Five Prime Therapeutics, Inc. (FPRX) $130 million for a variety of chimeric antigen receptor (CAR) T cell therapies, as the scrappy gene therapy firm attempts to muscle its way into the crowded, and lucrative, immuno-oncology space. Under the terms of the deal, Bluebird will pay $1.5 million up […]

White-hot CAR-T darling Juno Therapeutics (JUNO) is at it again, announcing Thursday that is has inked a massive $727 million deal with Editas Medicine , the gene editing company, for a partnership that will forge three research programs marrying Editas’ technologies, including CRISPR/Cas9, to Juno’s CAR and TCR technologies. Under the terms of the deal, […]

Novartis Presents New Data On 21 Medicines And 11 Investigational Compounds At ASCO And EHA   Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell lung cancer (NSCLC) and first Phase II data for Tafinlar and Mekinist in […]

A monitor shows the image of a breast cancer at a centre run by the ”Reto” Group for Full Recovery of Breast Cancer in Mexico City October 18, 2012. Reuters/Edgard Garrido A group of international researchers is making the case that genetic tests that look for multiple hereditary genes suspected of being linked to breast […]

GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. However, the drug reduced HBsAg, an antigen that indicates the strength of hepatitis B infection, after 48 weeks, the company said on Wednesday. GlobeImmune is developing the drug, GS-4774, […]

Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a “robotic pill” for complex biotech drugs that would normally have to be given by injection. Rani said it would run feasibility studies over the next 18-24 months to evaluate how selected Novartis biologic medicines can be […]

NORTH CHICAGO, Ill., May 26, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan.1 GIFT-I evaluated genotype 1b (GT1b) chronic hepatitis C […]

Biotech was full of news this week on clinical trials for the eyes, the ears, and other body parts people don’t usually talk about. Catch up on your headlines here: Eleven Biotherapeutics Fails in Dry Eye Clinical Trial Cambridge, Mass.-based Eleven Biotherapeutics lost 75% of its value, ending the week at $3 a share, after […]